서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 34 of 34

Issue DateTitle / Author(s) / CitationFileAltmetrics
2002-06
A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer
DOI
2004-11
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma
DOI
2005-12
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I-E/IIE extranodal NK/T-cell lymphoma, nasal type
DOI
2006-11
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
DOI
2008-01
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
DOI
2008-05
Aggressiveness of cancer-care near the end-of-life in Korea

Keam, Bhumsuk; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Kim, Mi Ra; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue; Heo, Dae Seog

Japanese Journal of Clinical Oncology, Vol.38 No.5, pp.381-386

DOI
2008-06
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
DOI
2008-07
Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
DOI
2009-09
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
DOI
2009-10
Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
view fileDOI
2010-03
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
DOI
2010-03
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6
DOI
2010-06
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
DOI
2010-08
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
view fileDOI
2010-09
Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study

Rhee, Jiyoung; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Journal of Gastroenterology and Hepatology, Vol.25 No.9, pp.1537-1542

DOI
2011-06
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DOI
2011-10
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

Lim, Kyu-Hyoung; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Cancer Chemotherapy and Pharmacology, Vol.68 No.4, pp.1017-1026

DOI
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-04
The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen
2012-08
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer
DOI
2013-04
The beneficial effect of palliative resection in metastatic colorectal cancer
DOI
2014-02
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
DOI
2014-09
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
DOI
2015-01
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX
DOI
2015-03
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
view fileDOI
2015-04
Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma
DOI
2015-06
Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer
DOI
2015-12
A Possible Association Between Thyroid Cancer and Breast Cancer
DOI
2016-04
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications
DOI
2016-07
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
DOI
2017-12
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
DOI
2020-04
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
DOI
2021-02
Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer
DOI
2022-10
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
DOI
1